8-K: Option Care Health Boosts Buyback, Forecasts 2026 Growth

Option Care Health announced strong preliminary Q4 and full-year 2025 results, increased its share repurchase program to $1 billion, and provided positive 2026 financial guidance.

Summary

• Preliminary net revenue for Q4 2025 is expected to be between $1.46 billion and $1.47 billion.
• Preliminary GAAP net income for Q4 2025 is expected to range from $59.1 million to $62.4 million, with GAAP diluted EPS of $0.37 to $0.39.
• Preliminary Adjusted EBITDA for Q4 2025 is projected to be $123.7 million to $127.7 million, and Adjusted diluted EPS is expected to be $0.46 to $0.49.
• Full Year 2025 preliminary net revenue is estimated at $5.645 billion to $5.655 billion, representing 13% growth compared to 2024 midpoint.
• Full Year 2025 preliminary Adjusted EBITDA is expected to be $469.0 million to $473.0 million, reflecting 6% growth compared to 2024 midpoint.
• Full Year 2025 preliminary Adjusted diluted EPS is projected at $1.72 to $1.76, an increase of 10% compared to 2024 midpoint.
• Cash flow from operations for Full Year 2025 is expected to be below $320 million, partly due to strategic inventory purchases.
• For Full Year 2026, preliminary financial guidance includes net revenue of $5.8 billion to $6.0 billion (4% growth vs. 2025 midpoint).
• Full Year 2026 preliminary Adjusted EBITDA guidance is $480 million to $505 million (5% growth vs. 2025 midpoint).
• Full Year 2026 preliminary Adjusted diluted EPS guidance is $1.82 to $1.92 (7% growth vs. 2025 midpoint).
• The Board of Directors approved an increase to the 2025 share repurchase program authorization from $500 million to $1 billion on January 9, 2026.
• Approximately $95 million of shares were repurchased during Q4 2025, and $307 million during the full year 2025 under the program.
• As of December 31, 2025, the 2025 share repurchase program had approximately $193 million in remaining purchase capacity, with the expanded authorization adding an additional $500 million.

Sentiment

Score: 8

Explanation: The company reported strong preliminary 2025 results and provided positive 2026 guidance, despite some headwinds. The significant increase in the share repurchase program signals strong management confidence and commitment to shareholder value. The company is well-positioned in a growing industry.

Positives

• Delivered strong preliminary 2025 results with 13% revenue growth, 6% Adjusted EBITDA growth, and 10% Adjusted diluted EPS growth compared to 2024 midpoint.
• Increased the share repurchase program authorization from $500 million to $1 billion, signaling confidence in future performance and commitment to shareholder returns.
• Well-positioned for 2026 with projected 5% Adjusted EBITDA growth and 7% Adjusted diluted EPS growth, despite anticipated headwinds.
• Served over 315,000 patients in 2025, demonstrating expanded patient access and market penetration.
• Maintains a diversified revenue and gross profit mix, with no single therapy representing more than 4% of company gross profit, reducing concentration risk.
• Possesses a robust balance sheet with approximately $700 million in liquidity and a 1.9x Net Debt Leverage Ratio as of September 30, 2025.
• Demonstrated strong and consistent cash generation, with approximately $1.4 billion in operating cash flow from 2021 to Q3 2025.

Negatives

• Cash flow from operations for Full Year 2025 is expected to be below $320 million, partly attributed to strategic inventory purchases.
• The 2026 guidance incorporates a (400bps) revenue growth headwind and a gross profit headwind of ($25M) ($35M) related to Stelara and Stelara biosimilars conversion.

Risks

• Changes in laws, regulations, or trade policies applicable to the business model could negatively impact operations.
• Loss of relationships with managed care organizations and other non-governmental third-party payers poses a risk to revenue streams.
• Changes in the pharmaceutical industry, including limiting or discontinuing research, development, production, and marketing of pharmaceuticals compatible with services, could affect service offerings.
• Changes in market conditions and receptivity to services and offerings may impact demand.
• Pending and future litigation or potential liability for claims not covered by insurance could result in significant financial costs.
• The preliminary financial information is subject to completion of year-end close procedures and further financial review, meaning actual results may differ from these estimates.

Future Outlook

Option Care Health anticipates continued growth in 2026, projecting net revenue between $5.8 billion and $6.0 billion, Adjusted EBITDA of $480 million to $505 million, and Adjusted diluted EPS of $1.82 to $1.92. The company plans to accelerate profitable growth by expanding its therapy portfolio, collaborating with payer partners, and delivering excellent service, while prioritizing capital deployment for internal investments, strategic M&A, and periodic share repurchases. The 2026 guidance incorporates a revenue and gross profit headwind from Stelara and Stelara biosimilars conversion.

Management Comments

• Management is confident in the company's strategy and execution.
• The company is well positioned for 2026, with 5% Adjusted EBITDA growth translating to 7% Adjusted EPS growth, incorporating a Stelara and Stelara biosimilars-related headwind of ($25M) ($35M).
• Plans are to accelerate profitable growth by growing the core business, expanding the portfolio of therapies and pharma programs, collaborating with payer partners, and delivering excellent service.
• Capital deployment will be prioritized to continue reinvesting in the business, pursue adjacent and accretive M&A, and execute periodic share repurchases.

Industry Context

The U.S. Home Infusion industry is projected to grow at a high single-digit percentage annually, driven by therapy growth, cost pressures, and patient preference for aging in place. Option Care Health, as the nation's largest independent provider, is well-positioned to capitalize on this trend within a fragmented provider landscape, leveraging its national scale and diversified portfolio to meet growing demand for cost-effective home and alternate site care models.

Comparison to Industry Standards

• The U.S. Home Infusion industry is projected to grow high single-digit percentage annually, indicating a favorable market trend that Option Care Health is positioned to leverage with its projected 4% revenue growth in 2026.
• The fragmented provider landscape presents wide range of growth opportunities for Option Care Health, allowing it to expand capacity and capabilities through strategic initiatives and acquisitions like Intramed Plus.
• Option Care Health's national independent platform enables economies of scale while providing local responsiveness, a key competitive advantage in the home infusion market, supporting its ability to serve over 315,000 patients across all 50 states.

Corporate Governance

Stakeholder Impact

• Shareholders: Positive impact due to strong financial performance, positive future guidance, and increased share repurchase program, which can boost EPS and share price.
• Patients: Continued focus on serving over 315,000 patients with over 600 therapies, expanding access and improving outcomes through innovative services.
• Employees/Clinicians: Continued growth and expansion of services, including new infusion clinics and pharmacies, may lead to job stability and potential growth opportunities for the 8,000+ team members, including 5,000+ clinicians.
• Payer Partners: Continued collaboration and expansion of payer partnerships, with 96% coverage to insured lives, reinforces the company's market position.
• Suppliers/Pharmaceutical Companies: Continued expansion of therapy portfolio and pharma programs suggests ongoing and potentially increased business for pharmaceutical partners.

Next Steps

• Provide further information regarding full year 2026 financial guidance on its fourth quarter earnings call in February.
• Continue to repurchase shares under the expanded program, with timing dependent on market conditions, regulatory requirements, and corporate considerations.
• Accelerate profitable growth by growing the core business, expanding the portfolio of therapies and pharma programs, collaborating with payer partners, and delivering excellent service.
• Prioritize capital deployment for internal investments, strategic tuck-ins and near-adjacency acquisitions, and periodic share repurchases.

Key Dates

Recommendation

Option Care Health demonstrates robust financial health with strong preliminary 2025 results, including double-digit growth in revenue, Adjusted EBITDA, and Adjusted EPS. The 2026 guidance projects continued profitable growth, despite manageable headwinds from Stelara biosimilars. The significant increase in the share repurchase program to $1 billion underscores management's confidence in the company's valuation and commitment to enhancing shareholder returns. Operating in a growing home infusion market, the company's national scale, diversified portfolio, and strong cash generation profile position it for sustained long-term value creation. The current valuation, coupled with these positive indicators, makes it an attractive investment.

Keywords

Home Infusion, Alternate Site Infusion, Healthcare Services, Option Care Health, OPCH, Financial Results, Earnings Guidance, Share Repurchase, EBITDA, EPS, Revenue, J.P. Morgan Healthcare Conference, SEC Filing, 8-K